ArticleCell death & disease2022

SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs.

Hang Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.